摘要
丙型肝炎病毒(HCV)通过在宿主细胞内持续复制,导致慢性感染。目前用于治疗慢性丙型肝炎(CHC)的药物主要是聚乙二醇干扰素(PEG-IFN)和利巴韦林的联合用药。本文将就HCV的细胞入侵、复制、逃避宿主的固有和获得性免疫,以及抗HCV临床试验药物的最新进展做一综述。
Hepatitis C virus（HCV） can lead to chronic hepatitis C（CHC） in ways that favor viral replication and persistent infection.The current standard treatment for hepatitis C virus infection is the combination of pegylated IFN with ribavirin（PEG-IFN/RBV）.In the recent years there has been significant advances in the understanding of viral replication and the development of anti-virus agents.This review summarizes the current knowledge of HCV cell entry,replication,escaping host innate and adaptive immune responses and current clinical trails of anti-HCV drugs.
出处
《临床肝胆病杂志》
CAS
2011年第1期15-18,27,共5页
Journal of Clinical Hepatology
基金
国家传染病重大专项课题(2008ZX10002-013)
国家新药创制重大专项课题(2008ZXJ09009-002)
上海市重点学科建设项目(B901)
